Risk of major adverse cardiovascular events and venous thromboembolic events between patients with psoriasis or psoriatic arthritis on tumor necrosis factor inhibitors, interleukin 17 inhibitors, interleukin 12/23 inhibitors, and interleukin 23 inhibitors: An emulated target trial analysis
J Am Acad Dermatol 2025;92:1015-23 DOI: 10.1016/j.jaad.2024.12.025
Chen et al. investigated the risk of MACE and VTE among patients with biologic-naïve psoriasis or PsA receiving biologic therapy. No significant difference in the risks of MACE and VTE was found between new biologics (IL-17i, IL-12/23i, or IL-23i) and TNFi.